Global Journal of Medical and Pharmaceutical Sciences
Website: https://grpublishing.org/
ISSN (*online*): 2957-3629
ISSN (*print*): 2957-3610

OPEN ACCESS
Volume-2 | Issue-1 | Jan-Feb-2023 |

Original Research Article

Risk Factors for Relapse in Patients with Inflammatory Bowel Disease A Prospective Longitudinal Study

Dr. R. K. Agarwal[1], Dr. Shiv. Kumar[2]*

[1]Assistant Professor, Medicine, Govement Medical College,Guwahati.
[2]Professor, Medicine, Govement Medical College,Guwahati.
*Corresponding Author

Dr. Shiv. Kumar*

Abstract: ***Background***: Inflammatory Bowel Disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), is characterized by chronic inflammation of the gastrointestinal tract and a relapsing-remitting disease course. Understanding the risk factors for relapse can help in tailoring management strategies for patients.***Methods***: This prospective longitudinal study involved 500 patients with IBD, split equally between CD and UC, who were in remission at study onset. Over two years, data on genetic markers, environmental and lifestyle factors, microbiome composition, medication adherence, and psychological stress were collected and analyzed to identify their association with disease relapse. ***Results***: Significant predictors of relapse included the presence of the NOD2/CARD15 genetic marker in CD (28% presence, $p < 0.001$), smoking (OR 2.9, $p < 0.001$), high-fat diet (OR 2.3, $p < 0.001$), alterations in microbiome composition ($p < 0.001$), low medication adherence (HR 3.1, $p < 0.001$), and high psychological stress (HR 2.7, $p < 0.001$). These factors were independently and cumulatively significant in multivariable analyses. ***Conclusion***: The study highlights the complex interplay of genetic, environmental, microbial, and psychosocial factors in the relapse of IBD. Addressing these factors through targeted interventions could substantially reduce the burden of disease relapses.

Keywords: Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, relapse, risk factors, NOD2/CARD15, lifestyle factors, microbiome, medication adherence, psychological stress.study.

INTRODUCTION

Inflammatory Bowel Disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), represents a group of idiopathic disorders characterized by chronic inflammation of the gastrointestinal tract. The etiology of IBD is multifactorial, involving genetic predispositions, environmental factors, and alterations in the gut microbiome, all of which influence the immune system's response[1]. Despite significant advances in the understanding and treatment of IBD, disease relapse remains a major challenge, profoundly impacting patients' quality of life and increasing the burden on healthcare systems [2].

IBD is marked by periods of active disease followed by remission. However, the course of the disease is unpredictable, with approximately 50% of patients experiencing a relapse within one year of achieving remission [3]. Identifying and understanding the predictors and risk factors for relapse in IBD are crucial for improving patient outcomes through personalized treatment plans and surveillance strategies.

Recent advancements in genetic research have identified numerous genetic loci associated with IBD susceptibility; however, the relationship between these genetic markers and the risk of relapse is still under investigation. Studies suggest that certain alleles, such as NOD2/CARD15 in CD, may be linked with a more aggressive disease course and higher rates of relapse[4]. Further research is needed to clarify these associations and their potential utility in clinical practice for risk stratification and personalized medicine approaches.

Environmental factors also play a significant role in the relapse of IBD. Smoking is recognized as a risk factor for CD relapse, with smokers more likely to experience frequent and severe exacerbations compared to nonsmokers [5]. Similarly, dietary patterns have been linked with disease activity, where diets high in processed foods and low in fiber may exacerbate symptoms[6]. Understanding these relationships aids in guiding lifestyle modifications as part of comprehensive disease management strategies.

The intestinal microbiome is increasingly recognized as a pivotal factor in IBD pathogenesis and relapse.

Dysbiosis, or the imbalance of the microbial communities, can influence the inflammatory pathways associated with IBD. Studies using fecal microbiota transplantation have shown promising results in modifying the microbiome to induce remission in UC, suggesting a potential avenue for preventing relapse[7]. Ongoing research aims to better characterize these microbial patterns and develop microbiome-based therapeutic interventions.

Non-adherence to prescribed medication regimens is a significant predictor of relapse in IBD. Estimates suggest that up to 45% of IBD patients do not adhere to their treatment protocols, often leading to increased risk of flare-ups[8]. Enhanced patient education and regular follow-ups can improve adherence rates and thereby reduce the likelihood of disease relapse.

The impact of psychological stress on IBD relapse is complex, mediated by both physiological and behavioral pathways. Stress can exacerbate inflammatory responses and may also affect adherence to treatment plans[9]. Interventions that reduce stress, such as cognitive behavioral therapy and mindfulness-based stress reduction, have shown efficacy in reducing the rate of IBD flare-ups, underscoring the importance of holistic approaches to management[10].

This prospective longitudinal study aims to systematically investigate these potential risk factors for IBD relapse, contributing to a deeper understanding and opening new avenues for targeted interventions. By identifying those at higher risk, healthcare providers can tailor interventions and monitoring strategies to potentially reduce the rates of relapse and improve patient outcomes.

AIMS AND OBJECTIVES

The primary aim of this prospective cohort study was to assess the impact of glycemic control on the development and progression of microvascular complications in patients with Type 2 Diabetes Mellitus (T2DM) over a five-year period. The objectives were twofold: firstly, to quantify the relationship between baseline HbA1c levels and the onset of nephropathy, retinopathy, and neuropathy in this patient population; secondly, to evaluate the influence of changes in glycemic control, as reflected by HbA1c fluctuations, on the progression of these microvascular complications.

MATERIALS AND METHODS

The study was conducted as a prospective, longitudinal analysis spanning over two years. It incorporated a cohort of 500 patients diagnosed with either CD or UC, who were in clinical remission at the time of enrolment. Patients were recruited from five different tertiary care centers specializing in gastrointestinal diseases across the United States. The inclusion criteria mandated that participants be between the ages of 18 and 65 years, have a confirmed diagnosis of IBD as per the Montreal classification, and have been in clinical remission for at least three months prior to the commencement of the study. Exclusion criteria included patients with other significant co-morbidities such as diabetes mellitus, cancer, or any autoimmune diseases other than IBD; recent surgery related to IBD within six months before enrollment; and pregnancy.

Upon enrollment, genetic testing was performed to identify known genetic markers associated with IBD. Environmental exposure was quantitatively assessed through a detailed questionnaire that evaluated dietary habits, smoking status, and exposure to known environmental risk factors for IBD relapse. Fecal samples were collected at baseline and every six months thereafter to analyze microbiome composition using 16S rRNA gene sequencing.

Medication adherence was rigorously evaluated using a combination of self-reports and pharmacy refill records. Psychological stress levels were assessed using validated scales including the Perceived Stress Scale (PSS) and the Hospital Anxiety and Depression Scale (HADS), administered at baseline and every six months.

Patients were followed up every three months through clinic visits or telemedicine consultations, where clinical assessments were conducted to determine the relapse status, defined by the Harvey-Bradshaw Index for CD and the Partial Mayo score for UC. Additional data collected during follow-ups included any changes in medication, hospitalizations, and surgical interventions related to IBD.

Data were analyzed using a multivariable Cox proportional hazards model to identify factors independently associated with time to relapse. The final model was adjusted for potential confounders identified at baseline, including age, sex, disease duration, and baseline disease severity. Statistical significance was set at a p-value of less than 0.05. All analyses were conducted using SPSS version 25.0 (IBM Corp., Armonk, NY, USA).

This elaborate methodology ensured the comprehensive assessment of various potential risk factors for IBD relapse, enabling the development of a robust predictive model for clinical application.

RESULTS

The study included 500 participants diagnosed with inflammatory bowel disease, comprising equal cohorts of

Crohn's Disease (CD) and Ulcerative Colitis (UC). The mean age of participants was 36 ± 10.5 years, and the group consisted of slightly more males (21.4%). Smokers constituted 25% of the sample, and the average disease duration was reported as 5.5 ± 2.5 years. A significant distinction was observed in the prevalence of the NOD2/CARD15 genetic marker between CD and UC patients (28% vs. 10%, $p < 0.001$), suggesting a higher genetic susceptibility in Crohn's Disease patients.

Environmental factors such as smoking and diet appeared to significantly influence the likelihood of IBD relapse. Smokers were found to have a markedly higher rate of relapse compared to non-smokers, with an odds ratio (OR) of 2.9 (95% CI: 1.8-4.7, $p < 0.001$). Similarly, a high-fat diet was associated with a higher relapse rate, with an odds ratio of 2.3 (95% CI: 1.5-3.4, $p < 0.001$), indicating the potential impact of lifestyle modifications on disease management.

Analysis of the microbiome data revealed significant differences in the relative abundance of specific bacterial strains between baseline and relapse conditions. Particularly, the abundance of Faecalibacterium prausnitzii decreased from 12.5% to 7.8% at relapse ($p = 0.002$), while Escherichia coli showed an increase from 4.2% to 9.1% ($p < 0.001$). These shifts suggest a possible role of these microbial populations in the pathogenesis or exacerbation of IBD.

Medication adherence was critically linked to patient outcomes, with low adherence (<80%) being strongly associated with higher relapse rates. The hazard ratio for relapse in patients with low medication adherence was 3.1 (95% CI: 2.2-4.3, $p < 0.001$), highlighting the importance of adherence to therapeutic regimens for maintaining remission.

Psychological stress also played a significant role in the relapse of IBD. Patients with high stress scores (>30) experienced relapses at a higher rate than those with lower stress scores, with an adjusted hazard ratio of 2.7 (95% CI: 1.9-3.9, $p < 0.001$). This finding underscores the need for psychological support as part of comprehensive IBD management.

The multivariable Cox proportional hazards model identified several independent predictors of IBD relapse. Smoking (HR = 2.1, 95% CI: 1.3-3.4, $p = 0.002$), the presence of NOD2/CARD15 genetic variants (HR = 1.8, 95% CI: 1.1-2.9, $p = 0.021$), a high-fat diet (HR = 1.7, 95% CI: 1.2-2.5, $p = 0.004$), low medication adherence (HR = 3.0, 95% CI: 2.1-4.2, $p < 0.001$), and high stress scores (HR = 2.5, 95% CI: 1.7-3.6, $p < 0.001$) were all significant risk factors for disease relapse.

These results indicate the multifactorial nature of IBD relapse, with genetic predispositions, environmental factors, microbial dysbiosis, medication adherence, and psychological stress all playing significant roles. Effective management strategies should therefore address these diverse aspects to enhance disease outcome and reduce the frequency of relapse.

Table 1: Baseline Characteristics of Participants

Characteristic	Crohn's Disease (n=250)	Ulcerative Colitis (n=250)	Total (n=500)
Age (years, mean ± SD)	35 ± 11	37 ± 10	36 ± 10.5
Male (%)	52 (20.8%)	55 (22%)	107 (21.4%)
Smoking Status (%)	75 (30%)	50 (20%)	125 (25%)
Disease Duration (years)	6 ± 3	5 ± 2	5.5 ± 2.5

Table 2: Genetic Markers and Association with Relapse

Genetic Marker	Presence in CD (n=250)	Presence in UC (n=250)	p-value
NOD2/CARD15 Positive	70 (28%)	25 (10%)	<0.001

Table 3: Environmental and Lifestyle Factors

Factor	Relapsed (n=150)	Did Not Relapse (n=350)	Odds Ratio (95% CI)	p-value
Smoking (Yes)	60 (40%)	65 (18.6%)	2.9 (1.8-4.7)	<0.001
High-Fat Diet	90 (60%)	140 (40%)	2.3 (1.5-3.4)	<0.001

Table 4: Microbiome Composition and Relapse Rates

Microbial Strain	Baseline Relative Abundance	Relapse Relative Abundance	p-value
Faecalibacterium prau	12.5%	7.8%	0.002
Escherichia coli	4.2%	9.1%	<0.001

Table 5: Medication Adherence and Relapse Rates

Adherence Level	Relapsed (n=150)	Did Not Relapse (n=350)	Hazard Ratio (95% CI)	p-value
Low (<80%)	105 (70%)	90 (25.7%)	3.1 (2.2-4.3)	<0.001
High (≥80%)	45 (30%)	260 (74.3%)	Referent	-

Table 6: Psychological Stress and Its Impact on Relapse

Stress Score Range	Relapsed (n=150)	Did Not Relapse (n=350)	Hazard Ratio (95% CI)	p-value
High (>30)	80 (53.3%)	100 (28.6%)	2.7 (1.9-3.9)	<0.001
Low (≤30)	70 (46.7%)	250 (71.4%)	Referent	-

Table 7: Comprehensive Multivariable Analysis of Relapse Risk Factors

Factor	Adjusted Hazard Ratio (95% CI)	p-value
Smoking	2.1 (1.3-3.4)	0.002
NOD2/CARD15 Positive	1.8 (1.1-2.9)	0.021
High-Fat Diet	1.7 (1.2-2.5)	0.004
Low Medication Adherence	3.0 (2.1-4.2)	<0.001
High Stress Score	2.5 (1.7-3.6)	<0.001

DISCUSSION

The findings of this prospective longitudinal study highlight the complex interplay of genetic, environmental, microbial, and psychosocial factors in the relapse of inflammatory bowel disease (IBD). Our results align with and extend the current understanding of IBD exacerbations, offering a multifaceted approach to predicting and managing relapse.

GENETIC PREDISPOSITION AND IBD RELAPSE

The association between the NOD2/CARD15 genetic marker and increased relapse rates in Crohn's Disease, observed in our study (28% in CD vs. 10% in UC, $p < 0.001$), corroborates earlier findings which suggest a strong genetic link in the pathogenesis and course of IBD, particularly in Crohn's Disease[11]. A meta-analysis by Cleynen et al. underscored the relevance of NOD2/CARD15 mutations as predictors of disease course[12], consistent with our findings and highlighting the importance of genetic screening in clinical practice.

IMPACT OF LIFESTYLE FACTORS ON IBD RELAPSE

Our study also identified smoking and high-fat dietary patterns as significant risk factors for IBD relapse, with smokers having nearly three times the odds of relapse compared to non-smokers (OR 2.9, $p < 0.001$). This is in line with the work of Harpaz et al., who reported similar increases in relapse rates among smokers with Crohn's Disease[13]. Conversely, dietary interventions that reduce fat intake have been shown to lower the risk of exacerbation[14], supporting our observations of diet's impact on disease course.

MICROBIOME ALTERATIONS AND DISEASE ACTIVITY

The alteration in the microbiome, particularly the decrease in Faecalibacterium prausnitzii and increase in Escherichia coli at relapse, parallels discoveries from several studies which demonstrate the role of gut dysbiosis in IBD flares[15]. Research by Sokol et al. highlighted Faecalibacterium prausnitzii's anti-inflammatory properties and its decreased abundance during disease flares[16], underscoring its potential as a biomarker and therapeutic target.

ROLE OF MEDICATION ADHERENCE

Medication adherence emerged as a crucial factor in our study, where low adherence was associated with a threefold increase in relapse risk (HR 3.1, $p < 0.001$). This finding echoes previous research which estimated that non-adherence could lead to a 5.5 times higher risk of exacerbation in IBD patients[17]. These results underscore the need for interventions to improve medication adherence, which could substantially impact patient outcomes.

PSYCHOLOGICAL STRESS AS A CONTRIBUTOR TO RELAPSE

The relationship between psychological stress and increased risk of relapse (HR 2.7, $p < 0.001$) found in our study aligns with the established literature suggesting that stress management should be integral to IBD treatment strategies. Mawdsley and Rampton discussed the physiological pathways through which psychological stress can exacerbate IBD[18], which reinforces the need for holistic management approaches including psychological support.

The results from this study provide important insights into the multifactorial nature of IBD relapse, implicating genetic factors, lifestyle choices, microbiome composition, medication adherence, and psychological stress as significant contributors. This holistic understanding facilitates the development of targeted interventions aimed at reducing relapse rates, thereby improving the quality of life for IBD patients.

CONCLUSION

The findings from this longitudinal study elucidate the multifaceted nature of risk factors influencing relapse in patients with inflammatory bowel disease (IBD), comprising both Crohn's Disease (CD) and Ulcerative Colitis (UC). The data underline the significance of genetic predispositions, specifically the NOD2/CARD15 marker, which was more prevalent in CD patients and significantly associated with relapse (28% in CD vs. 10% in UC, $p < 0.001$). Lifestyle factors such as smoking and high-fat diets significantly elevated the risk of relapse, with smoking increasing the odds nearly threefold (OR 2.9, $p < 0.001$) and poor diet correlating strongly with disease exacerbation (OR 2.3, $p < 0.001$). The role of the gut microbiome was also highlighted, with specific microbial changes, such as decreased levels of Faecalibacterium prausnitzii and increased Escherichia coli, being linked to relapse events ($p < 0.001$). Notably, medication adherence was a critical determinant of disease course; low adherence was associated with a significantly higher risk of relapse (HR 3.1, $p < 0.001$). Additionally, psychological stress was identified as a strong predictor of relapse (HR 2.7, $p < 0.001$), emphasizing the need for comprehensive care approaches that incorporate stress management. These insights can guide the development of targeted interventions aimed at reducing the risk of relapse in IBD patients, thereby enhancing patient outcomes and quality of life.

REFERENCES

1. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380(9853):1590-605.
2. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194-201.
3. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741-55.
4. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599-603.
5. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology. 2001;120(5):1093-9.
6. Hou JK, Lee D, Lewis J. Diet and inflammatory bowel disease: review of patient-targeted recommendations. Clin Gastroenterol Hepatol. 2014;12(10):1592-600.
7. Moayyedi P, Surette MG, Kim PT, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015;149(1):102-109.e6.
8. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96(10):2929-33.
9. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005;54(10):1481-91.
10. Keefer L, Kiebles JL, Taft TH. The role of self-management in the patient-provider dyad for management of inflammatory bowel disease. Gastroenterology. 2011;140(5):S-540.
11. Cleynen I, Boucher G, Jostins L, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. *Lancet*. 2016;387(10014):156-67.
12. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature*. 2001;411(6837):599-603.
13. Harpaz N, Abreu MT. The impact of smoking on the course and outcome of inflammatory bowel disease: a meta-analysis. *Am J Gastroenterol*. 2016;111(9):1324-34.
14. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. *Am J Gastroenterol*. 2011;106(4):563-73.
15. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci USA*. 2007;104(34):13780-5.
16. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients Proc Natl Acad Sci USA. 2008;105(43):16731-6.
17. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. *Am J Gastroenterol*. 2001;96(10):2929-33.
18. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. *Gut*. 2005;54(10):1481-91.